Phosphagen. Share Discussion Threads

[worc0670] 12/1/2007 12:13

Good news but the volume trading here is pathetic. Is everyone just watching the cricket?

[spaceparallax] 12/1/2007 09:35

Good news.

Estseon,

That sounds like a very bad idea - I think that your reluctance was well founded. Unless of course you have so many you don't know what to do with them.

[estseon] 12/1/2007 08:34

Charles Street Securities phoned me the other day suggesting that I sell part of my holding in PSG to fund a further investment in an electronics firm that they are bringing to AIM. The small amount of recent selling might have been others of their clients being persuaded to take some profits. I'm glad that I resisted the temptation. However, if there is a bout of selling on AIM following this news, it could be related to that (and nothing to do with the outlook or prospects of PSG).

[rambutan2] 12/1/2007 08:02

good news.

[flintsurfer] 12/1/2007 03:54

Looking very tasty!

[suesean1] 12/1/2007 03:30

Bloody computer playing up.

Good news


News Releases




12 January 2007











The Manager

Company Announcements Office

The Australian Stock Exchange Limited

Dear Sir



Re: Nestlé Nutrition enters commercial discussions with Phosphagenics





Phosphagenics Ltd ("Phosphagenics") (ASX Code: POH) (AIM Code: PSG) announced today that Nestlé Nutrition has exercised its option to finalise the existing commercial agreement to use Phospha-E® for the treatment and prevention of metabolic syndrome.



Under the terms of the option agreement, both parties must consent to all public announcements, and further details will be released once Phosphagenics has received Nestle Nutrition's consent.









Yours faithfully
Phosphagenics Limited



per Mourice Garbutt
Company Secretary







Contact details:



Mr Harry Rosen

Phosphagenics Ltd

Managing Director

[phone] or [phone]

[suesean1] 12/1/2007 03:17

12/01/2007 Nestle Nutrition Exercises Option

News out in Aus. 4.69% up as i type

[donaferentes] 11/1/2007 19:55

PSG is just to small to be acquired by Nestle - the transaction cost is not worth it, IMHO.

If I'm wrong, at least I'll be happy to realise a gain on these finally after a couple of very patient years.

[spaceparallax] 11/1/2007 17:12

Interesting - I wonder what implications this has for PSG?

[suesean1] 11/1/2007 16:52

Novartis Ag RPT Nestle plans 10 pct organic growth/yr in nutrition unit, seeks acquisitions


(Clarifies headline)
ZURICH (AFX) - Nestle SA said it aims for 10 pct annual organic growth in
its nutrition segment while also seeking acquisitions, citing Novartis AG's
Gerber unit as a potential target.
"We are aiming for 10 pct organic growth in the nutrition business," a
spokesman for the Swiss food giant said.
He added that Nestle was still seeking acquisitions and that the group might
well be interested in Novartis' Gerber unit, should the pharma group put Gerber
up for sale.
"We will definitely be among the companies taking a close look at Gerber,"
the spokesman said.
In Dec 2006 Nestle said it had agreed to acquire the medical nutrition
business of Novartis for a total amount of 2.5 bln usd

[donaferentes] 11/1/2007 11:24

Can't be bothered with the whole process - really badly handled and careless of UK shareholders. I don't know how their shareholders divide between Oz and UK, but if they want serious money for future development the UK is a much bigger capital market than Oz.

Still no reply from the management to my email before Xmas - poor show indeed.

[spaceparallax] 11/1/2007 09:41

At this rate, we'll be able to buy shares on the open market at the 12p price.

[rambutan2] 07/1/2007 20:01

recently on ci ty wire. i reckon psg stands a good chance of a nice rerating sometime in 07...

Norwich Union is evaluating the investment opportunities stemming from the world's obesity epidemic, which is expected to have sweeping implications for companies in the food, healthcare and leisure sectors.

The UK's largest insurer believes, for example, that healthcare companies that produce treatments for obesity-related illnesses such as diabetes and joint replacements, and food companies that specialise in health food are likely to experience increased demand.

Peter Michaelis, manager of Norwich Union's UK Ethical fund and Sustainable Future UK Growth fund, said: 'Obesity is a key theme for Norwich Union's Sustainable Future funds. We see this as an investment issue because it can affect companies' long-term profitability.'

Norwich Union's view comes in response to World Health Organisation statistics that reveal over one billion adults in the world are overweight, and 300 million are considered obese. Childhood obesity is also epidemic in some areas, and an estimated 17.6 million children under age five are overweight.

In the UK, the costs of obesity have reached £3.3 to £3.7 billion per year according to the House of Commons Health select committee.

[elfman] 04/1/2007 18:04

Graph looks like we should bounce from here.

[sf5] 30/12/2006 20:49

I agree this hardly seems worth the hassle for UK holders, which is a pity. The application form also specifies the AUS$5000 cheque or bankers draft must be drawn on an Australian bank. Presumably our local high street banks can't provide this?

I will contact the brokers I originally got my shares from in Dec 2004 - several UK people subscribed at that time - to see if they can offer a simpler solution.

Simon

[donaferentes] 29/12/2006 11:14

Thanks -//ax. Will check in with Self-trade in January to see if they are going to issue a circular to CREST holders.

Since I've long missed the boat to increase my holding by December 18 record date, it makes no odds now, as long as I decide by Jan 19. Still don't even know if size of existing holding is relevant to allowable subscription for the SPP. Not at all impressed with PSG's commitment to keeping its major capital market properly informed - frequently have to look at the website to find material reports that would have been RSN'd by any other AIM company.

As to subscribing under the SPP, it's a time-risk decision. I suspect my money could sit there a while longer going nowhere whilst it could have been taking short term 30-40% gains elsewhere. On the other hand, if you believe the story which I do, when it does go it will go off like a rocket and I may miss lift off. So, I either believe and wait patiently for a 5-bagger (minimum) after say 3 years, or I hedge my bets with shorter terms gains over say 2 years pf may be doubling my money and take a doubling of PSG in year 3 for an effective 4-bagger at lower risk that PSG never takes off.

Good luck to all holders in 2007!

[spaceparallax] 27/12/2006 11:22

Dona,

Just received details - need to pay via chq, bank draft or money order in $aus. To reach the share registry by 19 Jan.

Max purchase $Au5000 worth (16666shares)

You might be able to obtain details from [e-mail]

I'm going to mull it over for a few days; however, the hassle of the Oz chq etc might outweigh the marginal benefit cf share price discount.

Good luck

[donaferentes] 22/12/2006 15:23

Anyone seen the terms of the Share Purchase Plan relevant to UK holders?

Holding via CREST, selftrade have not yet sent me anything.

If possible to post here or mention a weblink - much appreciated.

TIA.

[donaferentes] 18/12/2006 14:25

I see from Friday's times that Nestle paid £1.27bn for Novartis Medical Nutrition which gives them cricitcal mass in USA. Seems like they have serious ambitions in Nutraceuticals. Sorry, no time to find web-link.

[suesean1] 17/12/2006 12:42

April 06, refresher.


Nestle Nutrition obtains option for Phospha E food





Second animal study links Phospha E to heart health
Phosphagenics forecasts strong growth from vitamin E phosphate
Enhanced vitamin E cuts cholesterol in animal study


28/4/2006 - Nestle Nutrition may develop products for metabolic syndrome using Phospha E, an advanced form of vitamin E that has shown promise in protecting against and alleviating the condition in animal trials.

The division of the Swiss food and beverage giant has obtained the option to licence Phospha E for use in nutritional products from Australian biotech company Phosphagenics, in exchange for a contribution towards the costs of a preclinical study, prior to full-scale evaluation in humans.
Phospha E is patented vitamin E phosphate, said to protect the antioxidant potential of vitamin E during absorption, transport and storage in the body. It is currently only marketed in the US, Canada and Indonesia by Zila Nutraceuticals, which markets it as Ester-E.

Phosphagenics managing director Harry Rosen said: "Nestle Nutrition is the ideal partner to exploit the potential of Phospha E in nutritional products."

The amount of Nestle's contribution to the preclinical trial funding has not been revealed. If it decides to exercise its option on completion of the trial a fee will be payable, and it will have a 12 month window following regulatory approval of the product and claims within which to bring a product to market.

Metabolic syndrome is characterised by a collection of factors, including overweight/obesity, high triglycerides, low HDL cholesterol, elevated blood pressure, and insulin resistance. It is a major risk factor for cardiovascular disease and diabetes.

In the United States, as much as 27 percent of the adult population has metabolic syndrome. With expanding waistlines and unhealthy eating habits across the Western world, metabolic syndrome rates in other countries could be almost on a par.

Two animal studies have indicated that Phospha E could have a beneficial effect on cardiovascular health, supporting the move to human trials.

In the first, mice fed a high cholesterol diet plus Phospha E for eight weeks were seen to have 40 per cent lower LDL cholesterol after just two weeks, and 44 percent lower plasma triglyceride levels after four weeks.

In the second, the results announced in October 2005 showed up to a 44 per cent lowering of LDL cholesterol levels in the blood of mice fed a normal diet supplemented with Phospha E, and a 51 percent decrease in triglycerides.

In both studies, a comparison with a normal vitamin E showed no significant benefit

[donaferentes] 16/12/2006 22:44

The option fee was paying for the research. If you mean the exercise price - that will be the terms of the distribution deal, not a cash sum IMHO.

[worc0670] 16/12/2006 16:13

Anyone know how much the option fee is?

[jjbaumhardt] 16/12/2006 13:43

"Nestle will generate more money from selling healthy food than chocolate from next year, after it agreed to pay $2.5bn (£1.3bn) cash for Novartis' medical nutrition unit" Daily Telegraph 15.12.06.

Any opinion on effect on PSG positive or negative?

JJB

[spaceparallax] 14/12/2006 12:17

Interesting to see what Nestle decide to do.